Oral nucleic acid therapy using multicompartmental delivery systems.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

• Publication date

  2018-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/wnan.1478PMID 28544521PMCID PMC5701888
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• FDA rejects first cognitive claim for antidepressant

  2016cited by this paper
• EMA greenlights second gene therapy

  2016cited by this paper
• Mutation in HFE gene decreases manganese accumulation and oxidative stress in the brain after olfactory manganese exposure.

  2016cited by this paper
• Loss of divalent metal transporter 1 function promotes brain copper accumulation and increases impulsivity

  2016cited by this paper
• Small Bowel, Celiac Disease and Adaptive Immunity

  2015cited by this paper
• Are RNAi and miRNA therapeutics truly dead?

  2015cited by this paper
• An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia

  2015cited by this paper
• Oxidative stress in traumatic brain injury.

  2014cited by this paper
• IL‐15: a central regulator of celiac disease immunopathology

  2014cited by this paper
• Influence of Lead on Repetitive Behavior and Dopamine Metabolism in a Mouse Model of Iron Overload

  2014cited by this paper
• Mucosal gene therapy using a pseudotyped lentivirus vector encoding murine interleukin-10 (mIL-10) suppresses the development and relapse of experimental murine colitis

  2014cited by this paper
• Cardiac Involvement in Hemochromatosis

  2014cited by this paper
• Immune Responses to AAV-Vectors, the Glybera Example from Bench to Bedside

  2014cited by this paper
• Multifunctional polymeric nanoparticles for oral delivery of TNF-α siRNA to macrophages.

  2013cited by this paper
• Agranulocytosis with deferiprone treatment of superficial siderosis

  2013cited by this paper
• Deferoxamine attenuates iron-induced long-term neurotoxicity in rats with traumatic brain injury

  2013cited by this paper
• Mipomersen: a lipid-lowering agent with a novel mechanism of action

  2013cited by this paper
• Delivery materials for siRNA therapeutics.

  2013cited by this paper
• Mipomersen Sodium: First Global Approval

  2013cited by this paper
• Polymer gene delivery: overcoming the obstacles.

  2013cited by this paper
• Multi-compartmental oral delivery systems for nucleic acid therapy in the gastrointestinal tract.

  2013cited by this paper
• Why interleukin-10 supplementation does not work in Crohn's disease patients.

  2013cited by this paper
• Overcoming nonviral gene delivery barriers: perspective and future.

  2013cited by this paper
• Gene therapy clinical trials worldwide to 2012 – an update

  2013cited by this paper
• Supramolecular self-assembled nanoparticles mediate oral delivery of therapeutic TNF-α siRNA against systemic inflammation.

  2013cited by this paper
• Systemically administered gp100 encoding DNA vaccine for melanoma using water-in-oil-in-water multiple emulsion delivery systems.

  2013cited by this paper
• Iron loading impairs lipoprotein lipase activity and promotes hypertriglyceridemia

  2013cited by this paper
• Nucleic acid delivery: the missing pieces of the puzzle?

  2012cited by this paper
• Desferrioxamine-related ocular toxicity: A case report

  2012cited by this paper
• Multi-Compartmental Nanoparticles-in-Emulsion Formulation for Macrophage-Specific Anti-Inflammatory Gene Delivery

  2012cited by this paper
• Ebselen inhibits iron-induced tau phosphorylation by attenuating DMT1 up-regulation and cellular iron uptake.

  2012cited by this paper
• Multi-Compartmental Vaccine Delivery System for Enhanced Immune Response to gp100 Peptide Antigen in Melanoma Immunotherapy

  2012cited by this paper
• Celiac disease: an overview from pathophysiology to treatment.

  2012cited by this paper
• Anti‐TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics‐Based Dosing Paradigms

  2012cited by this paper
• Hereditary hemochromatosis: patient experiences of the disease and phlebotomy treatment

  2011cited by this paper
• Influence of DMT1 and iron status on inflammatory responses in the lung.

  2011cited by this paper
• Dual TNF-α/Cyclin D1 Gene Silencing With an Oral Polymeric Microparticle System as a Novel Strategy for the Treatment of Inflammatory Bowel Disease

  2011cited by this paper
• Oral TNF-α gene silencing using a polymeric microsphere-based delivery system for the treatment of inflammatory bowel disease.

  2011cited by this paper
• HFE gene variants affect iron in the brain.

  2011cited by this paper
• Effect of phlebotomy on lipid metabolism in subjects with hereditary hemochromatosis.

  2011cited by this paper
• Celiac disease and transglutaminase 2: a model for posttranslational modification of antigens and HLA association in the pathogenesis of autoimmune disorders.

  2011cited by this paper
• Importance of IL-10 Modulation by Probiotic Microorganisms in Gastrointestinal Inflammatory Diseases

  2011cited by this paper
• HFE H63D Polymorphism as a Modifier of the Effect of Cumulative Lead Exposure on Pulse Pressure: The Normative Aging Study

  2010cited by this paper
• A meta-analysis of cytokines in Alzheimer's disease.

  2010cited by this paper
• Orally delivered thioketal nanoparticles loaded with TNF-α-siRNA target inflammation and inhibit gene expression in the intestines.

  2010cited by this paper
• Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment.

  2010cited by this paper
• A meta-analysis of cytokines in major depression.

  2010cited by this paper
• Iron-overload cardiomyopathy: pathophysiology, diagnosis, and treatment.

  2010cited by this paper
• Knocking down barriers: advances in siRNA delivery

  2009cited by this paper
• Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease.

  2009cited by this paper
• Biological therapies for inflammatory bowel disease: controversies and future options

  2009cited by this paper
• Inflammatory bowel disease and mutations affecting the interleukin-10 receptor.

  2009cited by this paper
• Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: the ESCALATOR study

  2009cited by this paper
• Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload

  2008cited by this paper
• Enhanced mucosal and systemic immune response with squalane oil-containing multiple emulsions upon intranasal and oral administration in mice

  2008cited by this paper
• Against the grain: An overview of celiac disease

  2008cited by this paper
• Oral IL-10 gene delivery in a microsphere-based formulation for local transfection and therapeutic efficacy in inflammatory bowel disease

  2008cited by this paper
• Development of Novel Biodegradable Polymeric Nanoparticles-in-Microsphere Formulation for Local Plasmid DNA Delivery in the Gastrointestinal Tract

  2008cited by this paper
• Systemic Leukocyte-Directed siRNA Delivery Revealing Cyclin D1 as an Anti-Inflammatory Target

  2008cited by this paper
• Celiac disease: pathophysiology, clinical manifestations, and associated autoimmune conditions.

  2008cited by this paper
• Functional properties of multiple isoforms of human divalent metal-ion transporter 1 (DMT1).

  2007cited by this paper
• Unravelling the pathogenesis of inflammatory bowel disease

  2007cited by this paper
• The fundamental basis of inflammatory bowel disease.

  2007cited by this paper
• The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention

  2007cited by this paper
• Breast cancer metastasis suppressor 1 (BRMS1) inhibits osteopontin transcription by abrogating NF-κB activation

  2007cited by this paper
• Gastrointestinal distribution and in vivo gene transfection studies with nanoparticles-in-microsphere oral system (NiMOS).

  2007cited by this paper
• [Current status of the iron hypothesis of cardiovascular diseases].

  2007cited by this paper
• Long-term effects of experimental intracerebral hemorrhage: the role of iron.

  2006cited by this paper
• Formulation optimization for the nanoparticles-in-microsphere hybrid oral delivery system using factorial design.

  2006cited by this paper
• HFE mutations and Alzheimer's disease

  2006cited by this paper
• Brain iron metabolism.

  2006cited by this paper
• Small-molecule screening identifies the selanazal drug ebselen as a potent inhibitor of DMT1-mediated iron uptake.

  2006cited by this paper
• Accelerated transferrin degradation in HFE-deficient mice is associated with increased transferrin saturation.

  2006cited by this paper
• DMT1: which metals does it transport?

  2006cited by this paper
• RNAi-mediated gene silencing in non-human primates

  2006cited by this paper
• Rhodamine-RCA in vivo labeling guided laser capture microdissection of cancer functional angiogenic vessels in a murine squamous cell carcinoma mouse model

  2006cited by this paper
• The cyclin D1 proto-oncogene is sequestered in the cytoplasm of mammalian cancer cell lines

  2006cited by this paper
• Understanding heme transport.

  2005cited by this paper
• Future therapeutic options for celiac disease

  2005cited by this paper
• Slc11a2 is required for intestinal iron absorption and erythropoiesis but dispensable in placenta and liver.

  2005cited by this paper
• Physiology and Pathophysiology of Iron Cardiomyopathy in Thalassemia

  2005cited by this paper
• Overview and pathogenesis of celiac disease.

  2005cited by this paper
• Refractory coeliac disease.

  2005cited by this paper
• Infliximab in the treatment of steroid-dependent ulcerative colitis.

  2004cited by this paper
• Balancing acts: molecular control of mammalian iron metabolism.

  2004cited by this paper
• Desferrioxamine related maculopathy: A case report

  2004cited by this paper
• Argonaute2 Is the Catalytic Engine of Mammalian RNAi

  2004cited by this paper
• Minireview: Cyclin D1: normal and abnormal functions.

  2004cited by this paper
• Role of deferiprone in chelation therapy for transfusional iron overload.

  2003cited by this paper
• Signalling pathways of the TNF superfamily: a double-edged sword

  2003cited by this paper
• Interleukin-10 Therapy—Review of a New Approach

  2003cited by this paper
• Tumour necrosis factor alpha: a key regulator of adipose tissue mass.

  2003cited by this paper
• Local delivery of adenoviral vectors encoding murine interleukin 10 induces colonic interleukin 10 production and is therapeutic for murine colitis

  2003cited by this paper
• Poly(Ethylene Glycol)-Modified Gelatin Nanoparticles for Intracellular Delivery

  2003cited by this paper
• Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.

  2003cited by this paper
• Tumour necrosis factor alpha converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease.

  2002cited by this paper
• Long-Circulating Poly(Ethylene Glycol)-Modified Gelatin Nanoparticles for Intracellular Delivery

  2002cited by this paper
• Genetic polymorphisms and oxidative stress in heart failure.

  2002cited by this paper
• Gene Therapy Progress and Prospects: Nonviral vectors

  2002cited by this paper
• Tumour necrosis factor α converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease

  2002cited by this paper

• Re-engineering insulin for oral delivery: structural modifications, advanced formulation strategies, and future directions

  2026cites this paper
• Drug-delivery strategies using biomaterials in the field of nerve regeneration

  2025cites this paper
• Emerging nanotechnology-enabled siRNA oral delivery platforms.

  2025cites this paper
• A new intracellularly regulated release pattern controlled by coordinated carrier cracking and drug release

  2024cites this paper
• Intestinal Lymphatic Biology, Drug Delivery, and Therapeutics: Current Status and Future Directions

  2024cites this paper
• Biomaterial‐based gene therapy

  2023cites this paper
• Strategies for non-viral vectors targeting organs beyond the liver

  2023cites this paper
• Emerging nanotherapeutic strategies targeting gut-X axis against diseases.

  2023cites this paper
• Oral delivery of nucleic acid therapeutics: challenges, strategies, and opportunities.

  2023cites this paper
• Oral Delivery of Nucleic Acid Therapies for Local and Systemic Action

  2022cites this paper
• Nucleic acid strategies for infectious disease treatments: The nanoparticle-based oral delivery route

  2022cites this paper
• Bacteria-Based Microdevices for the Oral Delivery of Macromolecules

  2021influential citation
• Oligonucleotide Delivery across the Caco-2 Monolayer: The Design and Evaluation of Self-Emulsifying Drug Delivery Systems (SEDDS)

  2021cites this paper
• COMPOSITION AND PROPERTIES OF HIGH-POLYMER DNA FROM GONADS OF DIFFERENT SPECIES OF HYDROBIONTS

  2021cites this paper
• Oral Core-Shell Nanoparticles Embedded in Hydrogel Microspheres for the Efficient Site-Specific Delivery of Magnolol and Enhanced Antiulcerative Colitis Therapy.

  2021cites this paper
• Pharmacokinetics and Biodistribution Analysis of Small Interference RNA for Silencing Tissue Transglutaminase-2 in Celiac Disease After Oral Administration in Mice Using Gelatin-Based Multicompartmental Delivery Systems

  2020cites this paper
• The Nano-Intestine Interaction: Understanding the Location-Oriented Effects of Engineered Nanomaterials in the Intestine.

  2020cites this paper
• Oral delivery of non‐viral nucleic acid‐based therapeutics ‐ do we have the guts for this?

  2019cites this paper
• Molecular targets and therapeutic interventions for Iron induced neurodegeneration.

  2019cites this paper
• Site-specific intestinal DMT1 silencing to mitigate iron absorption using pH-sensitive multi-compartmental nanoparticulate oral delivery system.

  2019cites this paper
• Literature review of baseline information on non‐coding RNA (ncRNA) to support the risk assessment of ncRNA‐based genetically modified plants for food and feed

  2019cites this paper
• Oral Vaccine Delivery for Intestinal Immunity—Biological Basis, Barriers, Delivery System, and M Cell Targeting

  2018cites this paper
• Studies of Impending Oligonucleotide Therapeutics in Simulated Biofluids

  2018influential citation